0001209191-19-043148.txt : 20190724 0001209191-19-043148.hdr.sgml : 20190724 20190724195958 ACCESSION NUMBER: 0001209191-19-043148 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190724 FILED AS OF DATE: 20190724 DATE AS OF CHANGE: 20190724 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BRADBURY DANIEL CENTRAL INDEX KEY: 0001236397 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38984 FILM NUMBER: 19972143 MAIL ADDRESS: STREET 1: BIOBRIT, LLC STREET 2: 2223 AVENIDA DE LA PLAYA, SUITE 108 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CASTLE BIOSCIENCES INC CENTRAL INDEX KEY: 0001447362 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770701744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 820 S FRIENDSWOOD DRIVE STREET 2: SUITE 201 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 BUSINESS PHONE: 866-788-9007 MAIL ADDRESS: STREET 1: 820 S FRIENDSWOOD DRIVE STREET 2: SUITE 201 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2019-07-24 0 0001447362 CASTLE BIOSCIENCES INC CSTL 0001236397 BRADBURY DANIEL C/O CASTLE BIOSCIENCES, INC. 820 S. FRIENDSWOOD DRIVE, SUITE 201 FRIENDSWOOD TX 77546 1 0 0 0 Stock option (right to buy) 16.00 2019-07-23 Common Stock 30895 D Series A Preferred Stock Common Stock 112307 I By LLC Series B Preferred Stock Common Stock 128839 I By LLC Series C Preferred Stock Common Stock 23572 I By LLC Series D Preferred Stock Common Stock 140932 I By LLC Series E-1 Preferred Stock Common Stock 138250 I By LLC Series E-2 Preferred Stock Common Stock 44801 I By LLC Series E-3 Preferred Stock Common Stock 39855 I By LLC Series F Preferred Stock Common Stock 209005 I By LLC Convertible Promissory Note Common Stock 874537.48 I By LLC 25% of the shares shall vest on August 1, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter. All outstanding shares of Preferred Stock will automatically convert into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration at a rate of 1 share of Common Stock for each 1.219 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. The Reporting Person is the managing member of BioBrit, LLC, and has voting and investment power over the shares. The principal amount of the Convertible Promissory Note held by the Reporting Person is $874,537.48. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") will automatically convert into the number of shares of Common Stock that is equal to the Conversion Amount as of the closing date divided by 80% of the IPO price per share. /s/ Greg Acosta, Attorney-in-fact 2019-07-24 EX-24.3_865958 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all, by these presents, that the undersigned hereby constitutes and appoints each of Derek Maetzold, Frank Stokes and Greg Acosta, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of Castle Biosciences, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 17th day of July, 2019. /s/ Daniel Bradbury